US SEC Trading Suspension Halt Orders — February 26, 2026

27-02-2026

On February 26, 2026, Jupiter Neurosciences, Inc. received Nasdaq notices for non-compliance with the Minimum Bid Price Requirement (closing bid price < $1.00 for 30 consecutive business days from January 13 to February 25, 2026) and the MVLS Requirement (market value of listed securities below $35M for the same period), both critical for continued listing on Nasdaq Capital Market. However, the Company has 180 calendar days until August 25, 2026, to regain compliance by meeting $1.00 bid for 10+ consecutive business days and $35M MVLS for 10 consecutive days, with trading continuing uninterrupted under ticker JUNS. The Company plans to monitor and may pursue options like a reverse stock split, though success is uncertain.

• ·Nasdaq may require bid price maintenance beyond 10 days, up to 20 consecutive business days.
• ·Eligibility for second 180-day compliance period requires meeting MVLS and other initial listing standards (except bid price) and notifying intent to cure, potentially via reverse stock split.
• ·Designated disclosure channels: website https://jupiterneurosciences.com, X @jupiterneuro, Instagram @Nugevia.
• ·Address: 1001 North US HWY 1, Suite 504, Jupiter, FL 33477; Phone: (561) 406-6154.

27-02-2026

Datavault AI Inc. filed an 8-K on February 27, 2026 (AccNo: 0001104659-26-020936), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No financial metrics, transaction values, guidance changes, or operational details were disclosed. This represents a material negative development with no mentioned positives or offsets.

27-02-2026

reAlpha Tech Corp. filed an 8-K on 2026-02-27 disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule under Item 3.01, alongside Departure of Directors or Certain Officers under Item 5.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This multi-item filing signals a major negative development with delisting, which typically impairs liquidity and investor access, compounded by potential leadership changes. No quantitative financial metrics, transaction values, or period-over-period comparisons are disclosed.

27-02-2026

Envoy Medical, Inc. filed an 8-K on 2026-02-27 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, including transfer of listing. Item 8.01 reports other events, and Item 9.01 includes financial statements and exhibits. No financial metrics, transaction values, or period-over-period comparisons are disclosed.

• ·Multi-item 8-K filing (Items 3.01, 8.01, 9.01)
• ·Filed on 2026-02-27 with AccNo: 0001213900-26-021116

27-02-2026

Sphere 3D Corp. (NASDAQ: ANY) received notice from Nasdaq on February 26, 2026, confirming it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This resolves the deficiency initially notified on March 6, 2025. No further actions or ongoing issues related to this rule are mentioned.

• ·Registrant's principal executive offices: 243 Tresser Blvd, 17th Floor, Stamford, Connecticut, United States 06901
• ·Telephone number: (647) 952 5049
• ·IRS Employer Identification No.: 98-1220792
• ·Commission File Number: 001-36532

27-02-2026

CIMG Inc. announced on February 27, 2026, that it received a letter from Nasdaq on February 23, 2026, stating the Nasdaq Hearings Panel will consider the company's failure to timely file its Form 10-Q for the period ended December 31, 2025, as an additional basis for potential delisting under Nasdaq Listing Rule 5250(c)(1) during the monitor period. The company is working diligently to complete and file the overdue 10-Q, with no immediate impact on the trading of its common stock under the symbol 'IMG' on The Nasdaq Capital Market. This development heightens delisting risks amid ongoing compliance issues.

• ·Company website: http://www.ccmg.tech
• ·IR contact: ir@ccmg.tech, +852 70106695

27-02-2026

Ensysce Biosciences, Inc. received a Nasdaq deficiency notice on February 25, 2026, stating non-compliance with Listing Rule 5550(a)(2) as the common stock bid price closed below $1.00 for 30 consecutive business days. The company has 180 calendar days until August 24, 2026, to regain compliance by achieving a minimum bid price of $1.00 for at least 10 consecutive business days, with no immediate impact on trading under symbol ENSC. Failure to comply could lead to delisting, impairing liquidity, capital raising, and stock value.

• ·Company intends to monitor bid price and evaluate options like reverse stock split if needed
• ·Possible second 180-day compliance period if initial period fails and other standards met
• ·Delisting appeal possible to Nasdaq hearings panel, but no assurance of success

27-02-2026

Tenon Medical, Inc. received a Nasdaq notification letter on February 25, 2026, stating that its common stock (TNON) failed to maintain a minimum $1.00 closing bid price for 30 consecutive business days from January 9 to February 24, 2026, violating Listing Rule 5550(a)(2). The company has an initial 180-day compliance period until August 24, 2026, to achieve $1.00 for 10 consecutive business days, with potential for a second 180-day extension if other listing standards are met. While listing remains intact with no immediate delisting, failure to comply risks suspension and transfer from The Nasdaq Capital Market.

• ·Securities registered: Common Stock (TNON) and Warrants (TNONW) on Nasdaq.
• ·Company is an emerging growth company.
• ·Nasdaq requires public announcement under Listing Rule 5810(b).